A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis

Trial Details

  • 240 patients will be taking part in this study
  • Condition: Ulcerative Colitis
  • Intervention: Drug: Mirikizumab Drug: Placebo
  • Clinic: Delta Research Partners 608 Grammont Street, Monroe, Louisiana, United States

Summary

The main purpose of this study is to test the hypothesis that treatment with mirikizumab is superior to placebo in providing clinical benefit to participants with moderate to severe ulcerative colitis (UC). This study will also investigate how the body processes the drug.

Researchers

Raj bhandari headshot for dt trial listings
Gastroenterologist

Full Trial Details